卡培他滨、伊立替康联合放疗治疗局部进展期直肠癌44例临床观察

Clinical efficacy of combined XELIRI and radiotherapy in locally advanced rectal cancer

目的比较卡培他滨+伊立替康(XELIRI)联合放疗与5-氟尿嘧啶+醛氢叶酸(5-FULV)联合放疗治疗局部进展期直肠癌的效果。方法 87例局部进展期直肠癌患者随机分为研究组(n=44)和对照组(n=43),分别行XELIRI或5-FULV联合放疗,观察两组疗效、不良反应。结果两组病理完全缓解率、根治性切除率及保肛率差异无统计学意义(P>0.05)。研究组手足综合征、骨髓抑制、腹泻低于对照组(P<0.05),但恶心呕吐在两组间差异无统计学意义(P>0.05)。结论 XELIRI、5-FULV联合放疗在局部进展期直肠癌患者中均有较好疗效,但XELIRI联合放疗不良反应较少。

Objective To compare the effect of combined XELIRI(capecitabine plus irinotecan) versus 5-FULV(5-fluorouracil plus levoleucovorin) and radiotherapy in locally advanced rectal cancer(LARC). Methods Eighty-seven LARC cases were randomly treated with XELIRI + radiotherapy(study group, n=44) and 5-FULV + radiotherapy(control group, n=43). Clinical efficacy and adverse reactions were compared between two groups. Results Rates of pathological complete remission, radical removal and anal preservation were comparable between two groups(P>0.05). Hand foot syndrome, myelosuppression and diarrhea were lower in study group than in control group(P<0.05), while no statistical difference in nausea and vomiting was present between two groups(P>0.05). Conclusion Both XELIRI + radiotherapy and 5-FULV + radiotherapy are effective in LARC, with fewer adverse reactions in the former regimen.